Evidence map›Paper›PMID 40093003›Full record

ArticleFrontiers in immunology2025

Modulation and distribution of extracellular free water and tract deficits in rhesus macaques before and after the initiation of emtricitabine + tenofovir disoproxil fumarate + dotutegravir treatment.

Benedictor Alexander Nguchu, Yu Lu, Yifei Han, Yanming Wang, Jiaojiao Liu, Hongjun Li, Peter Shaw

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Benedictor Alexander Nguchu *Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, & Brain Health), Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yu Lu *Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, & Brain Health), Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yifei HanOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, & Brain Health), Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yanming WangCenter for Biomedical Imaging, University of Science and Technology of China, Hefei, Anhui, China.
Jiaojiao LiuDepartment of Radiology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Hongjun LiDepartment of Radiology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Peter ShawOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, & Brain Health), Wenzhou Medical University, Wenzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Understanding the specific timing of cART initiation, its effectiveness, and failures, as well as assessing how well the current cART regimens control viral replication and rebound, enhance immune function, and repair or curb early injury in the central nervous system ( Methods: Here, we use an animal model to provide controlled environments to understand how the bodies of Chinese-origin rhesus monkeys, both the immune system and Results and discussion: Our experimental data demonstrate that the immune system is compromised as early as 7 days after infection, with a rapid rise of

Indexed as

Body WaterEmtricitabineEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationHeterocyclic Compounds, 3-RingSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsDisease Models, AnimalDolutegravirMacaca mulattaMaleOxazinesPiperazinesPyridonesTenofovirViral LoadDolutegravirEmtricitabineEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesTenofovir7-stage SIV follow-up studyChinese-origin rhesus monkeysdiffusivity properties of fiber tissuesdrug resistanceEMTBL/FTC + DTG + TDF regimenextracellular free water volume fractionsimian immunodeficiency virusviral rebound

Identifiers

PMID40093003
PMCPMC11906442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.